Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

Lockdown

Sector expert Michael Ballanger interprets year-end investment tactics by looking back at a childhood encounter. "Gold is money; everything else is credit." —J.P. Morgan My first faithful dog Fido (circa 1963) and I used to play a game years ago before his eyes and ...

Virtual Healthcare Made Easy. Here’s How.

Mednow Inc. ( TSX-V.MNOW , OTCMKTS: MDNWF , Forum ) is a healthcare technology company offering virtual access with exceptional care. It provides virtual care with convenience and through an interdisciplinary approach to healthcare that is focused on the patient experie...

Aging in the New World Order of Managed Markets

After over 40 years in the world of money and markets, I have arrived at the conclusion that aging can be a double-edged sword where the advantages created by many years of experience are many times odiously offset by innate biases that become ingrained over time. It came...

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...

Cash Balances Could Push Stock Market Much Higher

HIGHEST IN A DECADE According to Lipper and The Wall Street Journal , money market balances were basically identical on October 30, 2019 and March 25, 2009. It is easy to understand how money market balances reached extremely high levels in March 2...

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/...

Peering into the Future of CBD and THC Topical Delivery Products

An innovative product development company with a patented skin delivery technology appears to be making major breakthroughs in the topical and transdermal cannabis space. On April 16, 2019, Ovation Science Inc. ( C.OVAT , Forum ) announced the launch of its new topical...

Health Insurance Sector Indicates Growth in the Near Future

As continuous reforms hit the healthcare industry in the United States, millions have pushed forward the demands for comprehensive and convenient medical coverage in the form of lth insurance business has faced some setbacks due to various changes in regulations limiting their...

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial

Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. Shares of Ovid Therapeutics Inc. (OVID:NASDAQ) are tra...
1 2 3 4 5 6 7 8